Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. filed a Form 144 disclosing a proposed sale of 1,554 common shares to be executed through Morgan Stanley Smith Barney LLC on 10/03/2025 on NASDAQ. The filing states these shares were acquired as Restricted Stock Units from the issuer on 10/01/2025 and were paid/settled on the same date. The filing also lists multiple consummated sales by Laurent Moll during the prior three months, including sales of 42,692 shares on 09/02/2025 and other 10b5-1 plan sales totaling tens of thousands of shares across July–October 2025. The company reports 42,649,917 shares outstanding, and the proposed sale represents a small fraction of that total.
Arteris, Inc. (AIP) filed a Form 144 notifying the proposed sale of 11,821 common shares with an aggregate market value of $133,104.46. The shares are to be sold on or about 10/03/2025 on NASDAQ.
The filing shows these shares were acquired as Restricted Stock Units from the issuer on 10/01/2025. The filer reported multiple sales in the prior three months, including sales of 94,245 shares on 08/05/2025 (gross proceeds $1,271,120.01) and other transactions on 09/02/2025, 09/04/2025, and 10/02/2025.
Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported transactions dated 10/01/2025 executed under a 10b5-1 trading plan adopted on June 5, 2025. The reporting person acquired 5,000 shares (transaction code M) at an effective price of $0.56 and sold 5,000 shares (transaction code S) at a weighted average price of $10.3089, with sale prices ranging from $10.16 to $10.51. After the transactions, the report shows 73,587 shares beneficially owned as to the non-derivative holdings and 85,000 shares when including derivative securities. The derivative shown is an option with a $0.56 exercise price exercisable beginning 10/01/2025 and expiring 10/23/2029. The filing is signed and dated 10/03/2025.
Arteris, Inc. reported a Form 144 notice showing an intended sale of 19,060 shares of its common stock by a holder using Morgan Stanley Smith Barney LLC as broker, with an aggregate market value of $200,130.00. The filing states the shares were acquired as Restricted Stock Units on 09/03/2024 and the planned approximate sale date is 10/02/2025 on NASDAQ. The issuer has 42,649,917 shares outstanding per the filing. The notice also lists multiple recent sales by the same person under a 10b5-1 plan and direct sales between 07/03/2025 and 09/09/2025, totaling tens of thousands of shares and several hundred thousand dollars in gross proceeds.
Paul L. Alpern, who is listed as a director and as an officer (VP and General Counsel) of Arteris, Inc. (AIP), reported a set of transactions dated 09/15/2025 made pursuant to a 10b5-1 trading plan adopted June 5, 2025. The filing shows an acquisition of 10,000 common shares at a $0.56 exercise/conversion price and a simultaneous sale of 10,000 common shares at a weighted average price of $8.8805 (sales executed across $8.73–$8.97). After these transactions, the reporting person’s direct beneficial ownership in common stock was reported as 73,587 shares. The derivative table shows the reporting person holds options exercisable 09/15/2025 with a $0.56 strike for 10,000 underlying shares and reports 90,000 derivative securities beneficially owned following the reported transactions. The filing is signed 09/17/2025.
Paul L. Alpern, who is listed as a director and as an officer (VP and General Counsel) of Arteris, Inc. (AIP), reported a set of transactions dated 09/15/2025 made pursuant to a 10b5-1 trading plan adopted June 5, 2025. The filing shows an acquisition of 10,000 common shares at a $0.56 exercise/conversion price and a simultaneous sale of 10,000 common shares at a weighted average price of $8.8805 (sales executed across $8.73–$8.97). After these transactions, the reporting person’s direct beneficial ownership in common stock was reported as 73,587 shares. The derivative table shows the reporting person holds options exercisable 09/15/2025 with a $0.56 strike for 10,000 underlying shares and reports 90,000 derivative securities beneficially owned following the reported transactions. The filing is signed 09/17/2025.
Form 144 notice for Arteris, Inc. (AIP) reports a proposed sale of 10,000 common shares to be executed through Morgan Stanley Smith Barney on 09/15/2025 with an aggregate market value of $87,500. The filer acquired these shares the same day by exercise of stock options and paid in cash. The filing also discloses insider sales over the prior three months totaling 9,448 shares for aggregate gross proceeds of $85,168.03, executed under both regular and Rule 10b5-1 plans. The notice includes the filer’s representation that no undisclosed material adverse information is known.
Arteris, Inc. (AIP) reporting person Nicholas B. Hawkins, Vice President and Chief Financial Officer, reported a sale of common stock on 09/09/2025 under a Rule 10b5-1 trading plan adopted June 4, 2025. The filing shows 3,660 shares were sold at a weighted average price of $8.6903, with the filing noting individual sale prices ranged from $8.51 to $8.83. After the reported sale, Mr. Hawkins beneficially owned 103,898 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/10/2025. The disclosure emphasizes the transaction was pursuant to a pre-established trading plan and offers to provide detailed per-price sale breakdowns upon request.
Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported sales of company common stock under a 10b5-1 plan. On 09/08/2025 he sold 424 shares at $8.98 per share, and on 09/09/2025 he sold 2,278 shares at a weighted average price of $8.689 per share. After these transactions he beneficially owned 73,587 shares. The Form 4 states the sales were made pursuant to a trading plan adopted June 5, 2025, and provides a price range of $8.51 to $8.82 for the multiple trades comprising the weighted average.
Arteris, Inc. (AIP) insider Form 4 summary: The company's Chief Operating Officer, Laurent R. Moll, reported multiple sales of common stock in early September 2025 executed pursuant to a 10b5-1 trading plan adopted March 12, 2025. On 09/05/2025 she sold 4,698 shares at a weighted average price of $8.8045, reducing her beneficial ownership to 394,681 shares. On 09/08/2025 she sold 8,129 shares at a weighted average price of $8.7434, reducing beneficial ownership to 386,552 shares. On 09/09/2025 she sold 151 shares at $8.61, leaving 386,401 shares beneficially owned. The Form 4 was signed by an attorney-in-fact.
Arteris, Inc. (AIP) Form 144 notice reports a proposed sale of 2,278 common shares with an aggregate market value of $19,568.02. The shares represent part of the company's 42,649,917 outstanding common shares and are scheduled for sale on 09/09/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filer acquired these shares as Restricted Stock Units on 04/01/2025, with payment dated the same day. The filing also lists four secondary sales by the same person in the prior three months totaling 6,170 shares for gross proceeds of $65,374.37.